Vera CEO sells 18,500 shares after option exercise

Vera Therapeutics, Inc. reported that its president and CEO, Marshall Fordyce, exercised options for 18,500 shares of Class A common stock on September 2, 2026 at an exercise price of $2.8968 per share and received the same number of shares.

Rhea-AI Filing Summary

Vera Therapeutics, Inc. reported that its president and CEO, Marshall Fordyce, exercised options for 18,500 shares of Class A common stock on September 2, 2026 at an exercise price of $2.8968 per share and received the same number of shares. On the same date, he sold 18,500 shares at a weighted-average price of $35.1158 per share under a Rule 10b5-1 trading plan adopted on January 9, 2026. Following the option exercise, he held 507,301 shares subject to the exercised option grant.

Insider Trade Summary 10b5-1

Exercise and Sale: 18,500 shares ($596K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Fordyce Marshall

Role PRESIDENT AND CEO

Sold 18,500 shs ($650K)

Approx. gross sale proceeds $650K

Approx. exercise cost $54K

Approx. pre-tax spread $596K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy) F3	18,500	$0.00	$0.00
Exercise	Class A Common Stock	18,500	$2.8968	$54K
Sale	Class A Common Stock F1, F2	18,500	$35.1158	$650K

Holdings After Transaction: Stock Option (Right to Buy) — 507,301 contracts (Direct); Class A Common Stock — 235,244 shares (Direct)

Footnotes (3)

1. F1. The sales were made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.
2. F2. The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.34, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
3. F3. 1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vested monthly thereafter.

Key Figures

Shares underlying option exercised: 18,500 shares Option exercise price: $2.8968 per share Shares sold: 18,500 shares +4 more

7 metrics

Shares underlying option exercised 18,500 shares Options for 18,500 shares of Class A common stock exercised on September 2, 2026

Option exercise price $2.8968 per share Exercise price for the stock option exercised on September 2, 2026

Shares sold 18,500 shares Class A common shares sold on September 2, 2026 following the option exercise

Weighted-average sale price $35.1158 per share Weighted-average price for shares sold in multiple transactions between $35.00 and $35.34

Option shares outstanding after transaction 507,301 shares Shares remaining subject to the reported stock option after the exercise

Option expiration date December 15, 2030 Expiration date of the exercised stock option grant

Rule 10b5-1 plan adoption date January 9, 2026 Date the written trading plan governing the reported sales was adopted

Key Terms

Rule 10b5-1(c), weighted-average price, vested

3 terms

Rule 10b5-1(c) regulatory

"meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934"

Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.

weighted-average price financial

"The price reported is a weighted-average price."

Weighted-average price is the average of multiple prices where each price is counted according to its size or importance—larger trades carry more weight than smaller ones, like averaging course grades by credit hours. It matters to investors because it gives a more realistic picture of the true price paid or received, helping assess trade execution, compare performance, calculate cost basis, and value positions more accurately than a simple average.

vested financial

"1/4 of the shares subject to the option vested on December 16, 2021"

FAQ

What insider transaction did VERA report for Marshall Fordyce on September 2, 2026?

Marshall Fordyce exercised options for 18,500 shares of Vera Therapeutics Class A common stock at $2.8968 per share and sold 18,500 shares on September 2, 2026 in a planned transaction.

At what prices were Marshall Fordyce’s VERA shares exercised and sold?

The options were exercised at an exercise price of $2.8968 per share. The resulting 18,500 shares were sold at a weighted-average price of $35.1158 per share, with individual sale prices ranging from $35.00 to $35.34.

Was the September 2, 2026 VERA stock sale by the CEO under a Rule 10b5-1 plan?

Yes. The filing states the sales were made under a written trading plan adopted on January 9, 2026 that meets the requirements of Rule 10b5-1(c) under the Securities Exchange Act of 1934.

How many option shares did Marshall Fordyce retain after the VERA option exercise?

After the September 2, 2026 option exercise, Marshall Fordyce held 507,301 shares subject to that option award, which has an exercise price of $2.8968 per share and an expiration date of December 15, 2030.

What type of securities were involved in Marshall Fordyce’s VERA Form 4 filing?

The Form 4 reports a stock option to acquire Vera Therapeutics Class A common stock, its exercise into 18,500 shares of Class A common stock, and the subsequent sale of 18,500 shares of Class A common stock.

What is the vesting schedule disclosed for the exercised VERA stock option?

The filing explains that one-quarter of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vested monthly thereafter.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/04/2026 - 04:16 PM Accepted by SEC EDGAR 09/04/2026 - 04:15 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Fordyce Marshall

(Last) (First) (Middle)

C/O VERA THERAPEUTICS, INC.

2000 SIERRA POINT PARKWAY, SUITE 1200

(Street)

BRISBANE CALIFORNIA 94005

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Vera Therapeutics, Inc. [ VERA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	PRESIDENT AND CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	09/02/2026		M		18,500	A	$2.8968	253,744	D
Class A Common Stock	09/02/2026		S(1)		18,500	D	$35.1158(2)	235,244	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.8968	09/02/2026		M			18,500	(3)	12/15/2030	Class A Common Stock	18,500	$0	507,301	D

Explanation of Responses:

1. The sales were made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.

2. The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.34, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.

3. 1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vested monthly thereafter.

	/s/ Joseph R. Young, Attorney-in-Fact	09/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)